Healthcare Industry News:  HIV/AIDS 

Biopharmaceuticals HIV/AIDS

 News Release - September 18, 2007

ISENTRESS(TM) (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks



Source: Merck

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.



RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!